Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.

Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW; Adolescent Medicine Trials Network for HIV/AIDS Interventions.

AIDS Res Hum Retroviruses. 2019 Jun 27. doi: 10.1089/AID.2018.0270. [Epub ahead of print]

PMID:
31115244
2.

Inclusion of mental health in global economic development.

Ng CH, Goodenow MM, Greenshaw AJ, Upshall P, Lam RW.

BJPsych Int. 2018 Nov;15(4):74-76. doi: 10.1192/bji.2017.23.

3.

Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.

Mullins TLK, Li SX, Bethel J, Goodenow MM, Hudey S, Sleasman JW; Adolescent Medicine Trials Network for HIV AIDS Interventions.

J Clin Virol. 2018 May;102:7-11. doi: 10.1016/j.jcv.2018.02.001. Epub 2018 Feb 7.

4.

Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.

Williams JC, Zhang X, Karki M, Chi YY, Wallet SM, Rudy BJ, Nichols SL, Goodenow MM, Sleasman JW.

J Leukoc Biol. 2018 Apr;103(4):671-680. doi: 10.1002/JLB.3A0717-294RR. Epub 2018 Jan 29.

5.

Internal pilot design for balanced repeated measures.

Zhang X, Muller KE, Goodenow MM, Chi YY.

Stat Med. 2018 Feb 10;37(3):375-389. doi: 10.1002/sim.7524. Epub 2017 Nov 21.

6.

HIV-1 Infection Primes Macrophages Through STAT Signaling to Promote Enhanced Inflammation and Viral Replication.

Appelberg KS, Wallet MA, Taylor JP, Cash MN, Sleasman JW, Goodenow MM.

AIDS Res Hum Retroviruses. 2017 Jul;33(7):690-702. doi: 10.1089/AID.2016.0273. Epub 2017 Apr 12.

7.

HPV Population Profiling in Healthy Men by Next-Generation Deep Sequencing Coupled with HPV-QUEST.

Yin L, Yao J, Chang K, Gardner BP, Yu F, Giuliano AR, Goodenow MM.

Viruses. 2016 Jan 25;8(2). pii: E28. doi: 10.3390/v8020028.

8.

Increased inflammation but similar physical composition and function in older-aged, HIV-1 infected subjects.

Wallet MA, Buford TW, Joseph AM, Sankuratri M, Leeuwenburgh C, Pahor M, Manini T, Sleasman JW, Goodenow MM.

BMC Immunol. 2015 Jul 24;16:43. doi: 10.1186/s12865-015-0106-z.

9.

Editorial: Passive aggressive avoidance of SAMHD1 restriction by HIV-1.

Appelberg KS, Goodenow MM.

J Leukoc Biol. 2015 Jul;98(1):1-3. doi: 10.1189/jlb.4CE0215-044R. No abstract available.

PMID:
26130765
10.

Δ(9)-Tetrahydrocannabinol (THC) enhances lipopolysaccharide-stimulated tissue factor in human monocytes and monocyte-derived microvesicles.

Williams JC, Klein TW, Goldberger BA, Sleasman JW, Mackman N, Goodenow MM.

J Inflamm (Lond). 2015 Jun 12;12:39. doi: 10.1186/s12950-015-0084-1. eCollection 2015.

11.

Tracking the Emergence of Host-Specific Simian Immunodeficiency Virus env and nef Populations Reveals nef Early Adaptation and Convergent Evolution in Brain of Naturally Progressing Rhesus Macaques.

Lamers SL, Nolan DJ, Rife BD, Fogel GB, McGrath MS, Burdo TH, Autissier P, Williams KC, Goodenow MM, Salemi M.

J Virol. 2015 Aug;89(16):8484-96. doi: 10.1128/JVI.01010-15. Epub 2015 Jun 3.

12.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G, Hudey S, Goodenow MM, Sleasman JW; Adolescent Trials Network for HIVAIDS Interventions.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):52-60. doi: 10.1097/QAI.0000000000000549.

13.

Neglected tropical diseases among the Association of Southeast Asian Nations (ASEAN): overview and update.

Hotez PJ, Bottazzi ME, Strych U, Chang LY, Lim YA, Goodenow MM, AbuBakar S.

PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003575. doi: 10.1371/journal.pntd.0003575. eCollection 2015 Apr. Review.

14.

Spatiotemporal dynamics of simian immunodeficiency virus brain infection in CD8+ lymphocyte-depleted rhesus macaques with neuroAIDS.

Strickland SL, Rife BD, Lamers SL, Nolan DJ, Veras NM, Prosperi MC, Burdo TH, Autissier P, Nowlin B, Goodenow MM, Suchard MA, Williams KC, Salemi M.

J Gen Virol. 2014 Dec;95(Pt 12):2784-95. doi: 10.1099/vir.0.070318-0. Epub 2014 Sep 9.

15.

Effects of PRE and POST therapy drug-pressure selected mutations on HIV-1 protease conformational sampling.

Carter JD, Gonzales EG, Huang X, Smith AN, de Vera IM, D'Amore PW, Rocca JR, Goodenow MM, Dunn BM, Fanucci GE.

FEBS Lett. 2014 Aug 25;588(17):3123-8. doi: 10.1016/j.febslet.2014.06.051. Epub 2014 Jun 28.

16.

Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection.

Williams JC, Appelberg S, Goldberger BA, Klein TW, Sleasman JW, Goodenow MM.

J Neuroimmune Pharmacol. 2014 Jun;9(3):369-79. doi: 10.1007/s11481-014-9527-3. Epub 2014 Feb 23.

17.

Concordance between self-reported substance use and toxicology among HIV-infected and uninfected at risk youth.

Nichols SL, Lowe A, Zhang X, Garvie PA, Thornton S, Goldberger BA, Hou W, Goodenow MM, Sleasman JW.

Drug Alcohol Depend. 2014 Jan 1;134:376-382. doi: 10.1016/j.drugalcdep.2013.11.010. Epub 2013 Nov 19.

18.

IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus.

Yin L, Hou W, Liu L, Cai Y, Wallet MA, Gardner BP, Chang K, Lowe AC, Rodriguez CA, Sriaroon P, Farmerie WG, Sleasman JW, Goodenow MM.

Front Immunol. 2013 Nov 15;4:373. doi: 10.3389/fimmu.2013.00373. eCollection 2013.

19.

Empirical validation of viral quasispecies assembly algorithms: state-of-the-art and challenges.

Prosperi MC, Yin L, Nolan DJ, Lowe AD, Goodenow MM, Salemi M.

Sci Rep. 2013 Oct 3;3:2837. doi: 10.1038/srep02837.

20.

Longitudinal analysis of intra-host simian immunodeficiency virus recombination in varied tissues of the rhesus macaque model for neuroAIDS.

Lamers SL, Nolan DJ, Strickland SL, Prosperi M, Fogel GB, Goodenow MM, Salemi M.

J Gen Virol. 2013 Nov;94(Pt 11):2469-79. doi: 10.1099/vir.0.055335-0. Epub 2013 Aug 20.

21.

High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch.

Mild M, Gray RR, Kvist A, Lemey P, Goodenow MM, Fenyö EM, Albert J, Salemi M, Esbjörnsson J, Medstrand P.

Infect Genet Evol. 2013 Oct;19:369-77. doi: 10.1016/j.meegid.2013.05.004. Epub 2013 May 11.

PMID:
23672855
22.

High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems.

Yin L, Liu L, Sun Y, Hou W, Lowe AC, Gardner BP, Salemi M, Williams WB, Farmerie WG, Sleasman JW, Goodenow MM.

Retrovirology. 2012 Dec 17;9:108. doi: 10.1186/1742-4690-9-108.

23.

The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.

Wallet MA, Reist CM, Williams JC, Appelberg S, Guiulfo GL, Gardner B, Sleasman JW, Goodenow MM.

J Leukoc Biol. 2012 Oct;92(4):795-805. doi: 10.1189/jlb.0911447. Epub 2012 Jul 11.

24.

Unexpected maintenance of hepatitis C viral diversity following liver transplantation.

Gray RR, Strickland SL, Veras NM, Goodenow MM, Pybus OG, Lemon SM, Fried MW, Nelson DR, Salemi M.

J Virol. 2012 Aug;86(16):8432-9. doi: 10.1128/JVI.00749-12. Epub 2012 May 23.

25.

HPV-QUEST: A highly customized system for automated HPV sequence analysis capable of processing Next Generation sequencing data set.

Yin L, Yao J, Gardner BP, Chang K, Yu F, Goodenow MM.

Bioinformation. 2012;8(8):388-90. doi: 10.6026/97320630008388. Epub 2012 Apr 30.

26.

Efficient transmission and persistence of low-frequency SIVmac251 variants in CD8-depleted rhesus macaques with different neuropathology.

Strickland SL, Gray RR, Lamers SL, Burdo TH, Huenink E, Nolan DJ, Nowlin B, Alvarez X, Midkiff CC, Goodenow MM, Williams K, Salemi M.

J Gen Virol. 2012 May;93(Pt 5):925-38. doi: 10.1099/vir.0.039586-0. Epub 2012 Feb 1.

27.

Significant genetic heterogeneity of the SIVmac251 viral swarm derived from different sources.

Strickland SL, Gray RR, Lamers SL, Burdo TH, Huenink E, Nolan DJ, Nowlin B, Alvarez X, Midkiff CC, Goodenow MM, Williams K, Salemi M.

AIDS Res Hum Retroviruses. 2011 Dec;27(12):1327-32. doi: 10.1089/aid.2011.0100. Epub 2011 Jun 28.

28.

Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Haraguchi S, Ho SK, Morrow M, Goodenow MM, Sleasman JW.

J Leukoc Biol. 2011 Oct;90(4):653-60. doi: 10.1189/jlb.0111-009. Epub 2011 Apr 19.

29.

Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy.

Véras NM, Santoro MM, Gray RR, Tatem AJ, Lo Presti A, Olearo F, Cappelli G, Colizzi V, Takou D, Torimiro J, Russo G, Callegaro A, Salpini R, D'Arrigo R, Perno CF, Goodenow MM, Ciccozzi M, Salemi M.

AIDS Res Hum Retroviruses. 2011 Nov;27(11):1173-82. doi: 10.1089/AID.2010.0333. Epub 2011 May 6.

30.

Multiple independent lineages of HIV-1 persist in breast milk and plasma.

Gray RR, Salemi M, Lowe A, Nakamura KJ, Decker WD, Sinkala M, Kankasa C, Mulligan CJ, Thea DM, Kuhn L, Aldrovandi G, Goodenow MM.

AIDS. 2011 Jan 14;25(2):143-52. doi: 10.1097/QAD.0b013e328340fdaf.

31.

Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.

Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, Sleasman JW, Goodenow MM.

AIDS. 2010 Jun 1;24(9):1281-90. doi: 10.1097/QAD.0b013e328339e228.

32.

IFNgamma primes macrophages for inflammatory activation by high molecular weight hyaluronan.

Wallet MA, Wallet SM, Guiulfo G, Sleasman JW, Goodenow MM.

Cell Immunol. 2010;262(2):84-8. doi: 10.1016/j.cellimm.2010.02.013. Epub 2010 Feb 24.

33.

Proteome bioprofiles distinguish between M1 priming and activation states in human macrophages.

Brown J, Wallet MA, Krastins B, Sarracino D, Goodenow MM.

J Leukoc Biol. 2010 Apr;87(4):655-62. doi: 10.1189/jlb.0809570.

34.

Spatial phylodynamics of HIV-1 epidemic emergence in east Africa.

Gray RR, Tatem AJ, Lamers S, Hou W, Laeyendecker O, Serwadda D, Sewankambo N, Gray RH, Wawer M, Quinn TC, Goodenow MM, Salemi M.

AIDS. 2009 Sep 10;23(14):F9-F17. doi: 10.1097/QAD.0b013e32832faf61.

35.

Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Ho SK, Perez EE, Rose SL, Coman RM, Lowe AC, Hou W, Ma C, Lawrence RM, Dunn BM, Sleasman JW, Goodenow MM.

AIDS. 2009 Aug 24;23(13):1631-40. doi: 10.1097/QAD.0b013e32832e0599.

36.

Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents.

Yin L, Kou ZC, Rodriguez C, Hou W, Goodenow MM, Sleasman JW.

Clin Vaccine Immunol. 2009 Sep;16(9):1293-301. doi: 10.1128/CVI.00074-09. Epub 2009 Jul 15.

37.

HIV-1 activates macrophages independent of Toll-like receptors.

Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM.

PLoS One. 2008;3(12):e3664. doi: 10.1371/journal.pone.0003664. Epub 2008 Dec 2.

38.

An exploratory algorithm to identify intra-host recombinant viral sequences.

Salemi M, Gray RR, Goodenow MM.

Mol Phylogenet Evol. 2008 Nov;49(2):618-28. doi: 10.1016/j.ympev.2008.08.017. Epub 2008 Aug 31.

39.

Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

Ho SK, Coman RM, Bunger JC, Rose SL, O'Brien P, Munoz I, Dunn BM, Sleasman JW, Goodenow MM.

Virology. 2008 Sep 1;378(2):272-81. doi: 10.1016/j.virol.2008.05.029. Epub 2008 Jul 2.

40.

High-resolution structure of unbound human immunodeficiency virus 1 subtype C protease: implications of flap dynamics and drug resistance.

Coman RM, Robbins AH, Goodenow MM, Dunn BM, McKenna R.

Acta Crystallogr D Biol Crystallogr. 2008 Jul;D64(Pt 7):754-63. doi: 10.1107/S090744490801278X. Epub 2008 Jun 18.

PMID:
18566511
41.

The HIV type 1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries.

Salemi M, Goodenow MM, Montieri S, de Oliveira T, Santoro MM, Beshkov D, Alexiev I, Elenkov I, Elenkov I, Yakimova T, Varleva T, Rezza G, Ciccozzi M.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):771-9. doi: 10.1089/aid.2007.0181.

42.

Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.

Yin L, Rodriguez CA, Hou W, Potter O, Caplan MJ, Goodenow MM, Sleasman JW.

J Allergy Clin Immunol. 2008 Jul;122(1):166-72, 172.e1-2. doi: 10.1016/j.jaci.2008.04.029. Epub 2008 Jun 9.

43.

High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania.

Salemi M, de Oliveira T, Ciccozzi M, Rezza G, Goodenow MM.

PLoS One. 2008 Jan 2;3(1):e1390. doi: 10.1371/journal.pone.0001390.

44.

The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.

Coman RM, Robbins AH, Fernandez MA, Gilliland CT, Sochet AA, Goodenow MM, McKenna R, Dunn BM.

Biochemistry. 2008 Jan 15;47(2):731-43. Epub 2007 Dec 20.

PMID:
18092815
45.

Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies.

Salemi M, Burkhardt BR, Gray RR, Ghaffari G, Sleasman JW, Goodenow MM.

PLoS One. 2007 Sep 26;2(9):e950.

46.

Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease.

Coman RM, Robbins A, Goodenow MM, McKenna R, Dunn BM.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Apr 1;63(Pt 4):320-3. Epub 2007 Mar 30.

47.

HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes.

Goodenow MM, Collman RG.

J Leukoc Biol. 2006 Nov;80(5):965-72. Epub 2006 Aug 21. Review.

PMID:
16923919
48.

Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

Clemente JC, Coman RM, Thiaville MM, Janka LK, Jeung JA, Nukoolkarn S, Govindasamy L, Agbandje-McKenna M, McKenna R, Leelamanit W, Goodenow MM, Dunn BM.

Biochemistry. 2006 May 2;45(17):5468-77.

49.

Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.

Ghaffari G, Tuttle DL, Briggs D, Burkhardt BR, Bhatt D, Andiman WA, Sleasman JW, Goodenow MM.

J Virol. 2005 Nov;79(21):13250-61.

Supplemental Content

Loading ...
Support Center